{"id":"hdm-12-sq-hdm","safety":{"commonSideEffects":[{"rate":null,"effect":"Oral pruritus"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Mouth edema"},{"rate":null,"effect":"Local allergic reactions at administration site"}]},"_chembl":{"chemblId":"CHEMBL3653256","moleculeType":"Small molecule","molecularWeight":"555.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an allergen immunotherapy product designed to reduce allergic responses to house dust mites (HDM) by administering increasing doses of HDM extract sublingually (under the tongue). The mechanism involves immune tolerance induction, shifting the immune response from Th2-mediated allergic inflammation toward Th1/Treg-mediated tolerance, thereby reducing symptoms and medication dependence in HDM-allergic patients.","oneSentence":"HDM 12 SQ-HDM is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through gradual exposure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:55.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis and/or allergic asthma induced by house dust mite allergens"}]},"trialDetails":[{"nctId":"NCT07060885","phase":"PHASE3","title":"A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65","status":"RECRUITING","sponsor":"ALK-Abelló A/S","startDate":"2025-09-01","conditions":"Allergic Rhinoconjunctivitis, Allergic Rhinitis","enrollment":300},{"nctId":"NCT06741800","phase":"","title":"Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-20","conditions":"Rhinitis, Allergic","enrollment":100},{"nctId":"NCT06151938","phase":"","title":"Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis","status":"ENROLLING_BY_INVITATION","sponsor":"ALK-Abelló A/S","startDate":"2023-11-21","conditions":"Allergic Rhinitis Due to House Dust Mite, Allergic Asthma","enrollment":100},{"nctId":"NCT04176185","phase":"PHASE3","title":"A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber","status":"TERMINATED","sponsor":"ALK-Abelló A/S","startDate":"2019-11-04","conditions":"Allergic Rhinoconjunctivitis","enrollment":80},{"nctId":"NCT05119751","phase":"PHASE4","title":"Vestibular Versus Sublingual Route of AIT Tablets","status":"COMPLETED","sponsor":"Clinique Spécialisée en Allergies de la Capitale","startDate":"2021-10-25","conditions":"Hypersensitivity","enrollment":172},{"nctId":"NCT04100902","phase":"PHASE4","title":"The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2020-01-20","conditions":"Allergic Asthma Due to Dermatophagoides Pteronyssinus","enrollment":39},{"nctId":"NCT03746860","phase":"","title":"N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2018-05-09","conditions":"Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus","enrollment":1508},{"nctId":"NCT01383759","phase":"NA","title":"Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-06-24","conditions":"Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD)","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACARIZAX"],"phase":"marketed","status":"active","brandName":"HDM 12 SQ-HDM","genericName":"HDM 12 SQ-HDM","companyName":"Clinique Spécialisée en Allergies de la Capitale","companyId":"clinique-sp-cialis-e-en-allergies-de-la-capitale","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HDM 12 SQ-HDM is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through gradual exposure. Used for Allergic rhinitis and/or allergic asthma induced by house dust mite allergens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}